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49. Rashid G, Bernheim J, Green J et al. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. In the period before 2000, CV disease had been the most important cause of death both in dialysis and transplant patients, even after a long time period of living with a renal graft [6] . Other studies confirmed the extreme impact of CV disease in young patients with ESRD [2, 7] . Among the patients who had survived the LERIC study up to 2000, we found a high prevalence of CV comorbidity, compared with age-and gender-matched controls, reflected by an overall increased mean arterial wall stiffness, left ventricular hypertrophy (LVH) in 40% and by aortic calcifications in 19% of patients [7, 8] . In 2002, Oh et al. [9] reported similar CV abnormalities in young adults with chronic renal failure since childhood, including a 92% prevalence of calcifying arteriopathy and a significantly increased carotid intima media thickness compared with matched controls. Given this high prevalence of CV disease among the survivors of our cohort in 2000, we expected CV death to become an even more pronounced problem after 2000, as ageing would become an additional risk factor. To our surprise, however, we found that in the period 2000-10 CV mortality had dramatically decreased when compared with the period 1972-99 [MR 0.22 (95% CI 0.06-0.56) versus 0.67/100 per year (95% CI 0.44-0.98)] [10] . Although other recent studies have also reported a trend towards a decline in CV mortality in patients on RRT over the last years [6, 11, 12] , the size of the reduction in CV mortality in our study group was unexpected. Based on this finding, we hypothesized that increasing awareness of the CV burden of ESRD in the late nineties may have urged physicians to intensify cardioprotective management to reduce CV risk factors. In this study, we therefore aimed to investigate whether there was a decrease in the prevalence of CV risk factors potentially relating to changes in cardioprotective treatment over the past decade.
M E T H O D S

Study design
The LERIC cohort comprised all Dutch patients who had started chronic RRT between 1972 and 1992 at less than 15 years of age and who were born before 1979. In 1999-2000, the first follow-up study of these 249 patients was conducted [2, 7] . In addition, we performed an assessment of CV status including CV risk factors and intermediate outcomes like blood pressure and cardiac abnormalities at ultrasound. Of all 186 patients still alive at that time, 140 participated in this assessment. Participants (N = 140) and nonparticipants (N = 46) were similar in terms of age, disease severity, comorbidity, duration of RRT and therapy characteristics. In this article, we refer to these measurements as the 2000 measurements.
In 2009-2010, an extension of the follow-up study was conducted covering the period from the last chart review in 1999-2000 until the last chart review or the patient's death. These measurements will be referred to as the 2010 measurements. We attempted to localize all emigrated patients. In patients who were alive the day of review, and in patients were lost to followup or who had died the day of last seen or death was considered as the end of the observation period for that particular patient. For this study, we obtained permission from the medical ethical committee and informed consent from all patients.
Data collection
In 2000, assessment of cardiac abnormalities by ultrasound included B-and M-mode echo measurements on both the right and the left common carotid artery, according to the guidelines of the American Society of Echocardiography [13] . Left ventricular end-diastolic diameter, interventricular wall thickness during diastole and posterior wall thickness during diastole were measured by the same experienced cardiac sonographer [8] .
In 2000 and 2010, we collected, among others, data on potential risk factors for CV death and CV events. We considered obesity, hypertension, high cholesterol level, smoking habit, LVH and cardioprotective therapy, i.e. antihypertensive medication and cholesterol lowering medication, as potential positive or negative risk factors for CV death. We defined CV events as the occurrence of cerebrovascular accident (CVA), transient ischaemic attack (TIA) or myocardial infarction (MI). All information was derived from the medical charts of the patients. Hypercholesterolaemia was defined as: increased total cholesterol levels in combination with increased lowdensity lipoprotein (LDL) cholesterol levels. Blood pressure was scored as the mean blood pressure of all documented blood pressures over 6 months before the last day of chart review. Among haemodialysis patients, we used the mean of the pre-and postdialysis blood pressures. If no blood pressures were available in this period, the last documented blood pressure within 1 year from the study visit was used.
Hypertension was defined as having both a systolic blood pressure ≥140 mmHg and a diastolic blood pressure ≥90 mmHg.
Statistical analysis
The prevalence of CV risk factors and cardioprotective medication was calculated for 2000 and 2010, both for living and deceased patients. To adjust for the fact that the measurements were correlated as they took place within the same individual we calculated matched odds ratios (OR matched ).
R E S U LT S
Study population
In 2000, in 140 patients CV risk factors and outcomes were assessed. At that time, their median age was 28.7 years (range 20.6-40.9, Table 1 ). In 2010, the median total follow-up time from the start of RRT was 27.8 years (range 10.6-38.9). Between 2000 and 2010, out of 140 patients 22 died, two (1.4%) were lost to follow-up, while one patient (0.7%) had avoided medical care since 2007. Of the 116 patients still alive in 2010, 22 (18.6%) were treated with dialysis and 96 (81.4%) lived on a functioning graft. Of these transplanted patients, 28 (29.2%) received kidneys from a living and 68 (70.8%) from a deceased donor. This treatment distribution was very similar to the one in 2000 (Table 1) .
Cardiovascular outcomes
Between 2000 and 2010, of the 138 patients 22 (15.9%) patients died after a median follow-up on RRT of 24.0 years (range 10.7-32.3). Only 1 (0.7%) died due to CV disease (CVA), 9 (6.5%) patients died of an infection, 5 (3.6%) patients died due to a malignancy, 6 (4.3%) had another cause of death and for 1 (0.7%) patient the cause of death was unknown. Of the 138 patients, 11 (8.0%) experienced a CV event (MI, CVA or TIA) over the period 2000-10 resulting in an event rate of 0.95/100 py (95% CI 0.5-1.7), which was lower, although not statistically significant, than in the period 1972-2000 (1.75/ 100 py, 95% CI 1.3-2.4),
Main cardiovascular risk factors
We obtained information on recent echocardiographic data of 114 patients who were alive in 2010 and of 21 deceased patients within 1 year before death. Tables 2 and 3 show the change in CV risk factors and in cardioprotective therapy in Similar trends were seen in patients who died between 2000 and 2010, with the exception of BMI that did not change in deceased patients (Table 3 ). Furthermore, trends were similar in dialysis and transplantation patients.
Cardioprotective therapy
Cholesterol-lowering medication was more often prescribed in 2010 compared with 2000 [OR matched = 11.5 (95% CI 4.20-43.9), P < 0.01], whereas the increase of the number of patients using antihypertensive medication was borderline significant [OR matched = 2.09 (95% CI 0.98-4.75), P = 0.06 (Table 2) ]. The number of antihypertensive drugs per patient increased each year over the last decade, although not statistically significant [ Figure 1a ; >2 antihypertensive medication OR matched = 2.14 
O R I G I N A L A R T I C L E
D I S C U S S I O N
In this 10 years extension of a long-term follow-up study in patients with ESRD since childhood, we found a significant decrease in the prevalence of LVH, hypertension and hypercholesterolaemia over the last decade. We also found a trend towards a decrease in nonfatal CV events. CVA, TIA and MI decreased over the period 2000-10, compared with 1972-99. This was consistent with the significant decrease in CV death over the same period on which we previously reported [10] . We found a simultaneous significant increase in both cholesterol-lowering medication and antihypertensive medication, especially of ACE inhibitors/ARBs, between 2000 and 2010. Recent registry reports show that CV disease remains the most important cause of premature death in patients with ESRD. This accounts for all age groups [1, 6] . Among dialysis patients over the last decade, 23-30% suffered from ischaemic heart disease, according to the UK Renal Registry data and the USRDS [14, 15] . The USRDS reported unchanged rates of acute myocardial infarction (AMI), TIA and CVA between 2000 and 2010 [11] . Yet, recent studies also confirm a trend towards a decrease in CV casualties over the last decade and a concordant intensified management of CV disease in patients on RRT. According to the USRDS data, the rate of sudden cardiac death among haemodialysis patients fell from 70/1000 to 50/1000 per year between 2000 and 2010 [11] . The same trend was found in peritoneal dialysis patients. The data also show a significant decline of fatal AMI events among all dialysis patients over this period [11] . At the same time, both the use of antihypertensive medication and statins had increased over the last 3 years and most casualties were found in patients receiving no cardioprotective therapy [11] . Our findings imply that intensified cardioprotective therapy and more optimal control of hypertension, especially by ACE inhibitors or angiotensin receptor blockers may be effective in reducing LVH, cardiac events and cardiac death even after more than 20 years of RRT. In the late nineties, LVH was recognized as an important and strong independent determinant for decreased survival in ESRD patients and was shown to progress over time in most patients [16] . At the same time, LVH was considered to be more or less irreversible beyond the first years of haemodialysis [16] .
More recent studies however, although often small-sized and uncontrolled, confirm our findings that adequate cardioprotective therapy may indeed lead to reversal of cardiac abnormalities, such as LVH, in ESRD patients, as we found in our study. Optimized heart failure therapy with β-blockers, ACE inhibitors and ARBs, in combination with epoetin β to reach Hb targets has been shown to lead to a significant reduction of LVH, also among HD patients [17] [18] [19] . The efficacy of ACE inhibitors/ARBs in reducing LVH in dialysis patients has been confirmed in a systematic review [19] . Ibernon et al. [20] found a significant reduction in LVH in adult renal transplant recipients 2 years after transplantation that was closely related to adequate blood pressure control. Ardeleanu et al. [21] showed in a small study that a significant reduction in LVH in haemodialysis patients was possible even after a follow-up of 10 years. Other studies, with a follow-up of 3-5 years, showed that ACE inhibitors and use of ARBs have a role in preventing fatal and nonfatal CV events in the general population [22] [23] [24] [25] .
The direct impact of the use of ACE inhibitors and angiotensin receptor blockers on CV outcome in dialysis patients has been a matter of debate for a long time. Very recently, a systematic review confirmed the efficacy of angiotensin receptor blockers in reducing LVH in dialysis patients [26] . In transplanted patients, ACE inhibitors have been found effective in reducing left ventricular mass in a randomized trial [27] . These findings are in line with data from the ESCAPE study in children with CKD, in which the use of ACE inhibitors was associated with a reduction in the left ventricular mass index as well as with improvement of the myocardial function independent of the LVMI reduction [28] .
These studies and our findings are in contrast with most registry outcomes. Noncompliance with guideline recommendations for prevention of CV disease may be an important reason for the ongoing burden of cardiac disease in RRT patients. In an analysis of the data of European Society of Nephrology/European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA) database on the prevalence of hypertension in children on RRT, uncontrolled hypertension was found in 45.5% of all haemodialysis patients and in 35.5% of all PD patients [29] . According to the NAPRTCS data, even nearly 57% of all dialysis patients had uncontrolled hypertension [30] .
In adults, in a large quality intervention study, the MAURO study, only 45% of renal transplanted nonproteinuric patients met the targets for blood pressure control at baseline of the study, despite the fact that 95% received antihypertensive medication. For proteinuric and diabetic patients, normal blood pressures were found in only 14 and 18%, respectively [31] . In our study, using similar criteria, only 6.5% of the patients had hypertension. A better awareness among physicians of this problem and of the potential efficacy of cardioprotective therapy even in patients with a long-lasting burden of CV disease is essential to improve the overall outcome of patients with ESRD.
Limitations
Although this study is unique in its length of follow-up of patients who started RRT in childhood, our specific interest in long-term follow-up of young patients unfortunately hampers the comparison with registry data, as the latter are usually presented for overall groups or older age categories with and a relatively short follow-up.
In 2000, extra CV data could only be collected in 140 out of 186 patients. However, participants and nonparticipants were similar in terms of disease severity, CV risk factors, duration of RRT and therapy characteristics [8] . In 2000 echocardiography, to investigate LVH, was performed by one and the same experienced cardiac sonographer [8] . In 2010, however, we collected information on LVH from echocardiographic data assessed at the local sites, which may have influenced the detection of LVH. Changes in therapeutic strategies tackling CKD-metabolic bone disease or renal anaemia may also have contributed to the observed effect. Unfortunately, we were not able to collect reliable data on calcium exposure or on haemoglobin, PTH levels and vitamin D exposure; hence, we were not able to detect the influence of these changes in management on outcomes. Also changes in immunosuppressive treatment may have influenced CV outcome. However, we found no significant change in prescription of immunosuppressive therapy over the last 20 years with respect to drugs with an adverse CV profile, e.g. calcineurine inhibitors and steroids. Most patients who were transplanted before 2000 remained on the same regime between 2000 and 2010. Those patients who were transplanted after 2000 all received calcineurine inhibitors, contrary to patients with grafts from the seventies and early eighties only have been relative CV friendly regime with low dose prednisone and azathioprine.
CO N C L U S I O N
We found an unexpected reduction in CV events and risk factors for CV death in patients with paediatric onset of RRT over the last 10 years when compared with the period up to 2000. This was associated with a significant increase in cardioprotective therapy, even after more than 28 years of RRT. Although a causal relationship between the two cannot be inferred from this study, our data strongly suggest that a strict blood pressure control, especially by ACE inhibitors or angiotensin receptor blockers and reduction in dyslipidaemia may be effective in reducing cardiac threat in patients with ESRD even after a long lasting burden of CV disease.
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